Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer


External affiliation
Publication type
Article
Language
English
Access rights
Open access
Terms of use
CC BY-NC
Appears in Collections:
Metrics
Abstract
Immune checkpoint (IC) blockade using monoclonal antibodies is currently one of the most successful immunotherapeutic interventions to treat cancer. By reinvigorating antitumor exhausted T cells, this approach can lead to durable clinical responses. However, the majority of patients either do not respond or present a short-lived response to IC blockade, in part due to a scarcity of tumor-specific T cells within the tumor microenvironment. Adoptive transfer of T cells genetically engineered to express chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs) provide the necessary tumor-specific immune cell population to target cancer cells. However, this therapy has been considerably ineffective against solid tumors in part due to IC-mediated immunosuppressive effects within the tumor microenvironment. These limitations could be overcome by associating adoptive cell transfer of genetically engineered T cells and IC blockade. In this comprehensive review, we highlight the strategies and outcomes of preclinical and clinical attempts to disrupt IC signaling in adoptive T-cell transfer against cancer. These strategies include combined administration of genetically engineered T cells and IC inhibitors, engineered T cells with intrinsic modifications to disrupt IC signaling, and the design of CARs against IC molecules. The current landscape indicates that the synergy of the fast-paced refinements of gene-editing technologies and synthetic biology and the increased comprehension of IC signaling will certainly translate into a novel and more effective immunotherapeutic approaches to treat patients with cancer.
Reference
Rossetti R, Brand H, Lima SCG, Izadora Peter Furtado S, Silveira RM, Carvalho F DM, et al. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunother Adv. 2022 Jan; 2(2):ltac005. doi:10.1093/immadv/ltac005.
Link to cite this reference
https://repositorio.butantan.gov.br/handle/butantan/4466
URL
https://doi.org/10.1093/immadv/ltac005
Journal title
Issue Date
2022


Files in This Item:

ltac005.pdf
Description:
Size: 3.11 MB
Format: Adobe PDF
View/Open
Show full item record

This item is licensed under a Creative Commons License Creative Commons